Graphical Abstract Highlights d HMGB1 controls transition from pre-cancerous to cancerous lesions in skin d Epithelial HMGB1 promotes neutrophil recruitment and NET formation d TNF and RIPK1 activity mediate HMGB1-dependent NET formation and skin tumorigenesis d NET formation occurs in lesional and tumor-associated skin of RDEB patients
In Brief
Inflammation mediates tissue repair but can be hijacked to promote tumorigenesis. Hoste et al. demonstrate that HMGB1 delays regeneration and drives tumor formation in skin by recruitment and priming of neutrophils. These data indicate that therapies targeting HMGB1 or NET formation might be relevant in chronic and diabetic wound treatment.
SUMMARY
Regenerative responses predispose tissues to tumor formation by largely unknown mechanisms. High-mobility group box 1 (HMGB1) is a dangerassociated molecular pattern contributing to inflammatory pathologies. We show that HMGB1 derived from keratinocytes, but not myeloid cells, delays cutaneous wound healing and drives tumor formation. In wounds of mice lacking HMGB1 selectively in keratinocytes, a marked reduction in neutrophil extracellular trap (NET) formation is observed. Pharmacological targeting of HMGB1 or NETs prevents skin tumorigenesis and accelerates wound regeneration. HMGB1-dependent NET formation and skin tumorigenesis is orchestrated by tumor necrosis factor (TNF) and requires RIPK1 kinase activity. NETs are present in the microenvironment of keratinocyte-derived tumors in mice and lesional and tumor skin of patients suffering from recessive dystrophic epidermolysis bullosa, a disease in which skin blistering predisposes to tumorigenesis. We conclude that tumorigenicity of the wound microenvironment depends on epithelial-derived HMGB1 regulating NET formation, thereby establishing a mechanism linking reparative inflammation to tumor initiation.
INTRODUCTION
Danger-associated molecular patterns (DAMPs) activate the immune system upon injury and have key roles in cancer by either promoting inflammation or by driving the cytotoxic anti-tumor host response (Hernandez et al., 2016) . However, the specific contribution of individual DAMPs in these processes are still enigmatic. High-mobility group box 1 (HMGB1) is a multifunctional protein that serves as a transcriptional regulator in the nucleus but upon secretion acts as a DAMP, potently activating inflammation (Scaffidi et al., 2002) . HMGB1 performs its cytokine function by binding to various receptors, the best documented being RAGE (receptor for advanced glycation end products) and TLR-4 (Toll-like receptor 4) (Hori et al., 1995; Yang et al., 2010) . Increased levels of circulating HMGB1 have been shown to amplify the inflammatory responses that regulate tumor progression, invasion, and metastasis (Kang et al., 2013) , but the importance of HMGB1 in initiating neoplastic responses is largely unknown. In skin, we previously showed that flagellated bacteria can trigger TLR-5 activation in leukocytes, inducing the upregulation of cutaneous HMGB1 expression levels and the promotion of wound-induced tumorigenesis (Hoste et al., 2015) . Although HMGB1 has previously been implicated in tissue regeneration (Huebener et al., 2015; Straino et al., 2008; Tirone et al., 2018) , the molecular mechanisms through which this DAMP mediates wound repair and neoplastic events in skin are still unknown.
Chronic and acute wounding predisposes tissues to tumor formation (Arwert et al., 2012) . In skin, this association is remarkably clear in patients suffering from recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic cutaneous blistering disorder. Skin of RDEB patients constantly undergoes injury and repair, predisposing the epidermis to squamous cell carcinoma (SCC) formation (Fine et al., 2009) . We previously demonstrated that HMGB1 is abundantly secreted in SCC-associated skin of RDEB patients (Hoste et al., 2015) . Moreover, levels of circulating HMGB1 have been shown to correlate with RDEB disease severity (Petrof et al., 2013) . Neutrophils are the first immune cells recruited to wounded skin, where they can form neutrophil extracellular traps (NETs), enabling neutrophils to fight pathogens (Belaaouaj et al., 1998; Brinkmann et al., 2004) . NET formation is characterized by the release of neutrophil chromatin decorated with antimicrobial peptides in order to trap and potentially kill pathogens. Although being an important antimicrobial defense mechanism, NETs can also induce tissue damage, as is the case in diabetic conditions, where neutrophils are primed to form NETs, thereby delaying cutaneous wound healing (Menegazzo et al., 2015; Wong et al., 2015) . Since NETs have also been shown to impact on a plethora of diseases, including asthma and arthritis (Jorch and Kubes, 2017; Khandpur et al., 2013; Toussaint et al., 2017) , and have been observed in the microenvironment of various tumor types (Demers et al., 2016) , inhibiting NET formation might be an interesting therapeutic strategy to treat disease. One important cytokine that has been implicated in neutrophil priming is tumor necrosis factor (TNF) (Yuo et al., 1991) , which is also important for chemical-and wound-induced skin carcinogenesis (Hoste et al., 2015; Moore et al., 1999) , implicating a role for TNF in mediating NET formation downstream of HMGB1 release.
Here, we tested the hypothesis that a sole DAMP, namely HMGB1, impacts on pathological cutaneous remodeling and tumor initiation. We could demonstrate a crucial role for epithelialderived HMGB1 in regenerative and neoplastic inflammation and show that keratinocyte-specific HMGB1 primes neutrophils for NET formation in full-thickness skin wounds, resulting in delayed cutaneous wound closure and pro-tumorigenic signaling via TNF and RIPK1 kinase signaling. These findings identify epithelialderived HMGB1 as a crucial molecule mediating tumorigenicity of the wound microenvironment and suggest that HMGB1 neutralization or inhibition of NET formation may have potential as a therapeutic strategy to prevent skin cancer and accelerate cutaneous wound healing responses.
RESULTS

Keratinocyte-Specific HMGB1 Delays Wound Healing and Promotes Skin Tumor Formation
In order to understand the in vivo function of HMGB1 as a DAMP in cutaneous regenerative and neoplastic responses, we selectively deleted HMGB1 in keratinocytes or monocytes/macrophages by crossing HMGB1 ''floxed'' mice (Huebener et al., 2015) to mice expressing keratin-5 Cre or lysozyme M Cre , respectively (Figures S1A and S1B). Neither keratinocyte-specific HMGB1 knockout (D Ker HMGB1) mice nor myeloid-specific HMGB1 knockout (D myelo HMGB1) mice displayed overt phenotypes. However, when subjected to full-thickness skin wounding, healing rates were markedly accelerated in D Ker HMGB1 mice relative to littermate HMGB1 fl/fl (Cre negative) control mice (Figure 1A; Figure S1C) . Interestingly, wound healing rates were indistinguishable between mice lacking HMGB1 in myeloid cells and control littermates ( Figure S1D ). The accelerated wound healing rates observed in D Ker HMGB1 skin were not due to cell-autonomous keratinocyte effects, as primary keratinocytes in culture showed faster healing effects in scratch-wound assays in HMGB1-proficient versus HMGB1-deficient cultures (Figure S1E) . HMGB1 is upregulated in various chronically inflamed conditions (Degryse et al., 2001; Taniguchi et al., 2003) ; therefore, we next investigated wound healing responses in transgenic mice expressing a constitutively active MAP-kinase kinase 1 (MEK1) in differentiating keratinocytes (InvEE mice). These mice exhibit chronic skin inflammation, allowing the study of wound healing responses in a pathological skin context . Upon skin wounding, InvEE mice lacking HMGB1 in keratinocytes closed their wounds markedly faster than HMGB1-proficient InvEE mice ( Figure 1B ; Figure S1F ). In contrast, myeloid-cell-specific deletion of HMGB1 in InvEE mice did not result in altered wound closure rates ( Figure S1G ). Together, these data indicate that HMGB1 derived from keratinocytes, but not myeloid cells, plays an important role in reparative cutaneous inflammation.
HMGB1 has a context-dependent role in either promoting tumorigenesis by triggering chronic inflammation or in protecting from tumor development by eliciting immunogenic cell death (Hernandez et al., 2016; Kang et al., 2013) . To unravel the function of HMGB1 in cutaneous tumor initiation, we subjected InvEE mice lacking HMGB1 in either keratinocytes or in myeloid cells to wound-induced tumor formation. InvEE mice develop tumors at sites of full-thickness skin wounding with an incidence of 50% (Arwert et al., 2010) . Strikingly, D Ker HMGB1 mice were completely protected from wound-induced tumor formation ( Figure 1C ), while D myelo HMGB1 mice were equally sensitive to InvEE papillomagenesis ( Figure S1H ). Given that HMGB1 has important roles in the nucleus where it mediates the assembly of transcription factor complexes (Park et al., 2003; West et al., 2004) , we tested wound healing rates and skin tumorigenesis in the presence of Box A, an HMGB1 antagonist that prevents HMGB1 binding to its receptors (Kokkola et al., 2003) . In agreement with the faster wound healing rates observed in D Ker HMGB1 mice ( Figure 1B ), accelerated wound closure was also observed in InvEE mice that were intradermally injected with Box A at time of wounding and during early stages of repair ( Figure 1D ), and subsequent wound-induced tumor formation was strongly reduced upon Box A treatment ( Figure 1E ). Additionally, we intradermally injected mice with ethylpyruvate, an established inhibitor of HMGB1 secretion (Davé et al., 2009; Kim et al., 2016) , and also observed a protective effect on InvEE papillomagenesis ( Figure 1F ). In order to identify the receptor through which HMGB1 mediates regenerative and tumorigenic responses in skin, we next injected InvEE mice with antagonistic agents against RAGE or TLR-4. Both TLR-4 as well as RAGE neutralization resulted in enhanced wound closure in early post-wounding stages (Figures S1I and S1J). In addition, treatment with a monoclonal TLR-4 blocking antibody at the time of wounding and during the early post-wounding stages completely protected InvEE mice from tumor development (Figure 1G) . Treatment with a blocking peptide against RAGE also protected InvEE mice from wound-induced tumorigenesis, albeit to a lesser extent than treatment with a TLR-4 inhibiting antibody ( Figure 1H ). RNA sequencing of sorted live integrin-alpha 6-positive keratinocytes obtained from InvEE D Ker HMGB1 and InvEE and InvEE D Ker HMGB1 (n = 15) mice (B) after full-thickness wounding with an 8 mm punch biopsy (*p < 0.05; ***p < 0.001; ****p < 0.0001 between groups on respective days post-wounding; twoway ANOVA with multiple comparisons). (C) Incidence of papilloma formation in InvEE HMGB1 fl/fl (n = 26) and InvEE D Ker HMGB1 (n = 17) mice at site of wounding (**p = 0.002; Wilcoxon matched-pairs signed rank test). (D and E) Wound healing dynamics (D) and wound-induced tumor incidence (E) in InvEE HMGB1 fl/fl (n = 12) and InvEE D Ker HMGB1 (n = 12) mice intradermally injected with PBS (vehicle) or with Box A (n = 8) at time of wounding and 12, 24, and 36 h post-wounding (**p = 0.0016; *p < 0.05; two-way ANOVA with multiple comparisons). (F) Wound-induced tumor incidence in InvEE HMGB1 fl/fl mice intradermally injected with PBS (n = 16) or with ethylpyruvate (n = 7) at time of wounding and 12, 24, and 36 h post-wounding (**p = 0.0039; Wilcoxon matched-pairs signed rank test). (G) Wound-induced tumor incidence in InvEE HMGB1 fl/fl mice intradermally injected with IgG (n = 10) or with a monoclonal TLR-4-inhibiting antibody (n = 10) at time of wounding and 12, 24, and 36 h post-wounding (**p = 0.002; Wilcoxon matched-pairs signed rank test). (H) Wound-induced tumor incidence in InvEE HMGB1 fl/fl mice intradermally injected with PBS (n = 12) or with a RAGE antagonistic peptide (n = 8) at time of wounding and 12, 24, and 36 h post-wounding (**p = 0.002; Wilcoxon matched-pairs signed rank test). (I) Heatmap depicting mean expression of differentially expressed genes between InvEE HMGB1 fl/fl and InvEE D Ker HMGB1 keratinocytes. (J) Incidence of papilloma formation in HMGB1 fl/fl (n = 26) and D Ker HMGB1 (n = 17) mice treated with DMBA and TPA (****p < 0.0001; Wilcoxon matched-pairs signed rank test). (K) Representative photographs of HMGB1 fl/fl and D Ker HMGB1 mice treated with DMBA and TPA at week 7, 10, and 14 after start of TPA treatment. Wound healing data represent mean ± SEM. See also Figure S1. HMGB1-proficient mice indicated that HMGB1 is the sole cytokine that is differentially expressed in both genotypes ( Figure 1I ; Figure S1K ; GEO: GSE138918).
In order to confirm our observations in the InvEE model of wound-induced tumorigenesis in an independent skin tumor model, we next subjected D Ker HMGB1 and control littermates to the two-stage chemically induced DMBA/TPA (7,12-dimethylbenz(a)anthracene and 12-O-tetradecanoylphorbol-13-acetate) skin carcinogenesis model. In this model, skin cancer is induced by exposure to a single dose of DMBA inducing oncogenic mutations in HRas (initiation), followed by the repeated topical application with the phorbol ester TPA (promotion) allowing mutagenized cells to expand and form benign papillomas (Abel et al., 2009) . In agreement with the phenotype observed in woundinduced tumorigenesis, mice lacking HMGB1 in keratinocytes were also fully resistant to chemically induced tumor formation ( Figures 1J and 1K ). Together, these data prove that keratinocyte-derived HMGB1 is a key DAMP that delays regenerative wound healing responses and initiates neoplasia in chronically inflamed skin.
Keratinocyte-Specific HMGB1-Deficient Mice Exhibit an Exacerbated Cutaneous Response to TPA Treatment HMGB1, in its function as a DAMP, has been characterized as a potent pro-inflammatory mediator (Scaffidi et al., 2002; Wang et al., 1999) . To investigate whether the complete resistance of D Ker HMGB1 mice to chemically induced skin tumor formation was due to reduced inflammation upon treatment with the proinflammatory phorbol ester TPA, we examined the response of D Ker HMGB1 skin to topical TPA treatment. For this, D Ker HMGB1 and control littermate mice were repetitively treated with TPA for a total of two to six applications, and skin was collected 24 h after the last treatment ( Figure 2A) . Surprisingly, D Ker HMGB1 mice exhibited an exacerbated response to TPA relative to HMGB1 fl/fl control mice. After two topical TPA treatments, a significantly higher increase in transepidermal water loss (TEWL) was observed in D Ker HMGB1 compared to control mice. This response was even more pronounced in skin of D Ker HMGB1 mice treated six times with TPA ( Figure 2B ), indicating a more severe skin barrier perturbation in the absence of keratinocyte-derived HMGB1. In agreement, an increase in epidermal thickness could be observed in skin of TPA-treated D Ker HMGB1 mice relative to HMGB1 fl/fl skin ( Figures 2C and 2D ), again indicating a more severe tissue response to the pro-inflammatory exposure to TPA in D Ker HMGB1 skin relative to control skin.
To further discriminate between the effect of HMGB1 deficiency in keratinocytes on DMBA-induced tumor formation versus TPA-mediated tumor promotion, we subjected D Ker HMGB1 mice and control littermates to topical DMBA treatment twice a week for 15 weeks. D Ker HMGB1 mice were able to mount a tumor-protective response to treatment with the carcinogen alone, as tumor formation was strongly delayed upon DMBA treatment ( Figure 2E ). However, in contrast to the DMBA/TPA model, to which D Ker HMGB1 mice were fully resistant, tumors did arise in D Ker HMGB1 mice treated with DMBA alone, albeit far later and to fewer extent than in control littermates ( Figure 2E ; Figure S2 ). In conclusion, given that D Ker HMGB1 mice exhibit an enhanced sensitivity to epidermal bar-rier perturbation upon repetitive treatment with the phorbol ester TPA relative to their HMGB1 fl/fl littermates, the tumor-protective effect of HMGB1 ablation in keratinocytes does not result from a reduced inflammatory response in these mice. However, our data indicate that, depending on the type of epithelial damage, keratinocyte-derived HMGB1 can either protect from epidermal barrier perturbation or delay epithelial repair.
Epithelial-Derived HMGB1 Mediates Neutrophil Infiltration and NET Formation in Skin Wounds
Neutrophils represent the first immune cell type that is recruited to sites of injury. Interestingly, genes encoding for proteins involved in neutrophil infiltration, such as the chemokines Cxcl-2 and Ccl5 (RANTES), were significantly downregulated in TPA-treated D Ker HMGB1 mice relative to controls ( Figure 3A ). These findings are in agreement with the reduced neutrophil infiltration seen in livers of acetaminophen-intoxicated hepatocytespecific HMGB1-deficient mice (Huebener et al., 2015) . Therefore, we tested whether neutrophil infiltration is altered in wounds of mice lacking HMGB1 in keratinocytes. Indeed, as shown by flow cytometric analysis, the total amount of neutrophils (CD45+ CD11b+ Ly6-G+ cells) that infiltrated the skin at day 2 post-wounding was significantly lower in D Ker HMGB1 compared to HMGB1 fl/fl mice. In contrast, the total amount of macrophages (CD45+ CD11b+ CD64+ cells) present in these wounds did not differ between genotypes (Figures 3B and 3C) .
Neutrophils can form extracellular traps, termed NETs, which have been demonstrated to delay cutaneous wound healing responses (Wong et al., 2015) . Given that we observed slower wound closure in HMGB1 fl/fl relative to D Ker HMGB1 mice, we analyzed whether the level of NET formation was reduced in D Ker HMGB1 wounds. Western blot analysis of skin wound lysates showed prominent levels of citrullinated histone-3 (H3 citr ), an established marker for NET formation (Wong et al., 2015; Toussaint et al., 2017) , in HMGB1-proficient wounds, whereas H3 citr levels are barely detectable in D Ker HMGB1 wounds at day 2 post-wounding ( Figure 3D ). NETs are defined as neutrophilic extracellular DNA structures that colocalize with granule-derived proteins and histones (Konig and Andrade, 2016; Boeltz et al., 2019) . We performed immunofluorescent staining of externalized DNA (DAPI) and assessed colocalization with neutrophil elastase (NE) and H3 citr . Confocal microscopy of skin wounds of D Ker HMGB1 and HMGB1 fl/fl mice at early postwounding stage verified that NET formation was markedly reduced in D Ker HMGB1 wounds relative to control littermates ( Figure 3E ). NETs were also observed in the tumor stroma of wound-induced papillomas ( Figure 3E ) but were absent in unwounded D Ker HMGB1 and HMGB1 fl/fl mice. We also confirmed the reduced level of histone-3 citrullination in neutrophils in D Ker HMGB1 skin wounds by flow cytometric quantification of live neutrophils (CD45+ CD11b+ Ly6G+ cells) that stained for citrullinated histone-3 in D Ker HMGB1 and HMGB1 fl/fl wounds at day 2 post-wounding ( Figure 3F ), although it should be stated that this might be due to the reduced neutrophil infiltration observed in D Ker HMGB1 wounds. In conclusion, we could demonstrate that keratinocyte-derived HMGB1 drives neutrophil infiltration and NET formation in the early inflammatory response to fullthickness skin wounding, thereby providing in vivo relevance of HMGB1 acting as an upstream regulator of NET formation in skin reparative inflammation.
Altered NET Formation Impacts on Wound-Induced Tumorigenesis
The increased presence of NETs, delaying regenerative responses in skin, has recently been described in the context of diabetes (Menegazzo et al., 2015; Wong et al., 2015) . To investigate whether ablation of HMGB1 in keratinocytes affects woundinduced tumor formation in conditions where neutrophils are primed to NET formation, we subjected InvEE D Ker HMGB1 and InvEE HMGB1 fl/fl mice to streptozotocin (STZ)-induced type 1 diabetes. STZ-challenged InvEE D Ker HMGB1 diabetic mice developed wound-induced tumor formation with an incidence comparable to that of InvEE HMGB1 fl/fl mice ( Figure 4A ), indicating that in conditions that predispose neutrophils to NET formation, lack of epithelial-derived HMGB1 is no longer capable of protecting the skin from tumorigenesis. This acquired sensitivity to tumor development correlated with a less prominent reduction in NET formation in wounded STZ-induced D Ker HMGB1 diabetic mice relative to wounded STZ-induced wildtype diabetic mice, as demonstrated by western blotting for H3 citr levels ( Figure 4B ).
Digestion of NETs by DNase1 is sufficient to accelerate their clearance by macrophages (Farrera and Fadeel, 2013) . To assess the causative involvement of NETs in cutaneous wound-induced tumorigenesis, we next investigated whether inhibiting NETs by injecting DNase1 in InvEE mice could alter skin tumor susceptibility. Indeed, injection of DNase1 in HMGB1-proficient InvEE mice at the time of wounding and in the initial stages of wound healing resulted in a significant protection from woundinduced tumorigenesis ( Figure 4C) . In agreement, a significant (D) Epidermal thickness was measured on H&E sections by ImageJ software; 10 measurements per field were performed for 3 fields per mouse. The thickness of the epidermis was determined by measuring the distance from the basement membrane to the upper granular layer, excluding the cornified layers (****p < 0.0001; ***p = 0.0001; two-way ANOVA with multiple comparisons)). Data represent mean ± SEM. (E) Tumor incidence (% of mice with one or more tumors) in HMGB1 fl/fl (n = 14) and D Ker HMGB1 (n = 11) mice treated with DMBA (**p = 0.002; Wilcoxon matchedpairs signed rank test). See also Figure S2 . reduction in H3 citr levels could be observed in wound lysates after DNase1 treatment ( Figure 4D ). DNase1-injected mice also closed their wounds markedly faster than control-injected InvEE HMGB1 fl/fl mice ( Figure 4E ), recapitulating the effect of HMGB1 ablation from keratinocytes. Interestingly, DNase 1 treatment did not alter wound healing rates in D Ker HMGB1 mice (Figure S3A) . Of note, when epithelial damage was induced in InvEE HMGB1-proficient mice by repetitive topical TPA treatment, NETs could not be observed, and this type of injury did not result in tumor formation in InvEE mice ( Figure 4F ; Figure S3B ), demon-strating that the formation of NETs occurs only in specific conditions of epithelial damage where it can drive tumor initiation.
HMGB1 Secretion and the Presence of NETs Coincide in Wounded and Tumor-Bearing Skin
Our previous study demonstrated HMGB1 secretion in woundinduced tumors in mice as well as in patients suffering from the skin blistering disease RDEB (Hoste et al., 2015) . Immunofluorescent analysis revealed that HMGB1 is indeed highly upregulated in the murine wound and tumor microenvironment from control HMGB1 fl/fl mice ( Figure 5A) . At day 2 post-wounding, we observed the highest expression of HMGB1, both in the wound stroma and in the adjacent epidermis ( Figure 5A ). Residual completed, HMGB1 was still prevalent in wounded epidermis and underlying stroma of HMGB1 fl/fl mice, albeit to a lesser extent than at day 2 post-wounding ( Figure 5A ). We further observed higher levels of circulating HMGB1 levels in serum from wounded mice compared to unwounded mice, and these levels were even higher in serum of mice bearing skin tumors ( Figure 5B) .
The enhanced expression of HMGB1 in wounded skin was next confirmed by western blotting on HMGB1 fl/fl wound lysates ( Figure 5C ), and a significantly reduced HMGB1 expression could be confirmed in D Ker HMGB1 skin wounds compared to HMGB1 fl/fl controls, demonstrating that keratinocytes are the main source of HMGB1 during wound healing responses. The prominent upregulation of HMGB1 during the early post-wounding stage coincided with the highest expression of H3 citr (Figure 5C ), implicating the formation of NETs as an early and transient response to wounding. Interestingly, this early post-wounding time point also represents the period when most striking differences in wound healing responses are observed between keratinocyte-specific HMGB1-proficient versus -deficient mice ( Figures 1A and 1B) , indicating that HMGB1 induces the release of NETs mainly in the initial stages of wound healing, where they hamper regeneration and induce neoplastic events.
Keratinocyte-Specific HMGB1 Mediates Regenerative and Tumorigenic Responses through TNF and RIPK1 Kinase Activity
The proinflammatory cytokine TNF was previously shown to promote chemically induced skin carcinogenesis (Moore et al., 1999) . To examine whether TNF mediates cutaneous regenerative and tumorigenic responses downstream of HMGB1, we assessed the levels of TNF in circulation of wounded and unwounded InvEE D Ker HMGB1 mice relative to InvEE HMGB1proficient mice. Interestingly, a marked reduction in serum levels of TNF was observed in wounded InvEE D Ker HMGB1 mice relative to wounded InvEE HMGB1-proficient mice, while the levels of other proinflammatory cytokines that are known to be involved in skin carcinogenesis, such as IL (interleukin)-6 and IL-8 levels, were not significantly altered between wounded mice of both genotypes ( Figure 5D ). In agreement, staining for TNF in cutaneous wounds of InvEE D Ker HMGB1 and control mice confirmed reduced levels of TNF in wounds of mice lacking HMGB1 from keratinocytes ( Figure 5E ). Finally, TNF-blocking antibodies were injected in InvEE mice during the early post-wounding stage, demonstrating a significant reduction in wound-induced tumor formation compared to immunoglobulin G (IgG)-injected control mice ( Figure 5F ). Western blotting of wound lysates of In-vEE mice treated with and without TNF-blocking antibodies revealed that H3 citr levels were markedly reduced upon inhibition of TNF ( Figure 5G ). Recent work demonstrated that neutrophil Receptor-Interacting-Protein Kinase-1 (RIPK1)-dependent necroptosis drives NET formation (D' Cruz et al., 2018) . Since TNF mediates RIPK1dependent apoptosis and necroptosis, we next investigated whether wound-induced tumor formation depends on the kinase function of RIPK1. For this, kinase-dead RIPK1 (RIPK1 D138N ) mutant mice were generated in the InvEE genetic background, wounded, and monitored for skin papillomagenesis. InvEE RIPK1 D138N mice were strongly protected from wound-induced tumor development, demonstrating that RIPK1 kinase activity drives tumor formation ( Figure 5H ). Western blotting of wounded skin lysates confirmed that citrullination of histone-3 could not be observed in the absence of RIPK1 kinase activity ( Figure 5I ). In conclusion, these data show that TNF and subsequent RIPK1 activity act downstream of HMGB1 to mediate NET formation and cutaneous tumor formation.
HMGB1 Secretion by Human SCC Cells Induces Cell Death in Neutrophils
To investigate the relevance of enhanced HMGB1 expression for NET formation and tumor induction in human skin, we analyzed skin sections from RDEB patients. Immunofluorescent analysis of tissue sections obtained from RDEB patients demonstrated the presence of NETs in RDEB lesional and SCC-associated skin ( Figure 6A ), indicating that also in human skin, tumorigenicity of the wound microenvironment can be associated with the occurrence of NETs. To further validate this hypothesis, we analyzed the levels of secreted HMGB1 in the supernatant of normal human keratinocyte cell lines versus SCC cells and could observe a significant increase in HMGB1 release in SCC keratinocytes versus normal keratinocytes ( Figure 6B ). Finally, live imaging of human neutrophils incubated with conditioned medium of SCC versus normal keratinocytes revealed that neutrophil death is accelerated upon incubation of the cells with conditioned medium from SCC keratinocytes compared to conditioned medium from normal keratinocytes ( Figures 6C and 6D) .
Together, these data identify a crucial role for epithelialderived HMGB1 in driving tumorigenicity of cutaneous wounds by mediating the levels of NET formation by skin-infiltrating neutrophils in the early stages of wound repair. Upon pharmacological inhibition of HMGB1 or NET formation in this early postwounding stage, mice close their cutaneous wounds faster and are fully protected from keratinocyte-derived tumor initiation.
DISCUSSION
Regenerative inflammation can induce neoplastic responses; however, the molecular mechanisms underlying this association are largely unknown. Our data identified a crucial role for keratinocyte-derived HMGB1 in delaying cutaneous injury repair and in driving tumorigenicity of cutaneous wounds by mediating neutrophilic inflammation and NET formation in the early stages of wound repair. Mice close their cutaneous wounds faster and are fully protected from keratinocyte-derived tumor initiation when HMGB1 release or NET formation are prevented in the early post-wounding stage, suggesting that targeting HMGB1 or NETs might represent an interesting therapeutic avenue in reducing wound-associated skin tumorigenesis.
Neutrophils represent the main cell type involved in the early immune response during injury repair, where they can produce NETs that have recently been implicated in various infectious and inflammatory pathologies, including sepsis, liver injury, atherosclerosis, and asthma (Hernandez et al., 2018; Papayannopoulos, 2018; Toussaint et al., 2017; Warnatsch et al., 2015) . NETs can exert beneficial effects on wound healing due to their bactericidal effects Brinkmann et al., 2004) . However, antimicrobial factors such as neutrophil elastase and histones can also damage epithelia and delay wound healing, as is seen in conditions of excessive NET formation (Dovi et al., 2003; Wong et al., 2015) . Interestingly, the differences in wound healing rates observed in D Ker HMGB1 mice versus control mice are most obvious during the time frame in which NET formation occurs (Figures 1, 3, and 5) .
TNF also has a predominant damaging activity in wound healing and skin tumorigenesis and is highly potent in priming neutrophils. Our observation that both TNF neutralization as well as genetic inactivation of RIPK1 kinase activity protects mice from wound-induced tumorigenesis indicates a crucial role for HMGB1 in driving TNF-RIPK1 signaling to skin carcinogenesis ( Figure 5 ). This is in line with a previous report indicating that antibody-mediated depletion of HMGB1 in a model of LPS-induced lung inflammation dampened TNF-release and reduced NET formation (Tadie et al., 2013) .
Several molecular signaling pathways lead to the formation of NETs (Konig and Andrade, 2016) . One of these pathways was initially described by Zychlinski et al. and shown to be dependent on Nox2-mediated reactive oxygen species (ROS) production (Brinkmann et al., 2004; Fuchs et al., 2007) . An alternative and presumably antagonistic pathway of chromatin extrusion by neutrophils relies on calcium-dependent PAD4-mediated hypercitrullination (Wang et al., 2009 ). More recently, RIPK1-mediated necroptosis (Desai et al., 2016) and gasdermin D-mediated pore formation were also shown to facilitate the release of NETs. Our data identify a crucial role for NET formation associated with protein hypercitrullination in skin wounding and tumor initiation, consistent with an earlier study demonstrating NET accumulation in diabetic skin wounds (Wong et al., 2015) . Staining for NETs in wounded and tumor-bearing skin clearly showed reduced NET formation in the absence of keratinocyte-derived HMGB1 ( Figure 3E ). We cannot exclude additional NET-independent effects of keratinocyte-derived HMGB1 on neutrophil function. Indeed, decreased neutrophil infiltration in D Ker HMGB1 mice is in accordance with the role of HMGB1 as a cytokine. We hypothesize that HMGB1 critically contributes to exceeding the inflammatory threshold by the recruitment of neutrophils and the formation of NETs, thereby creating an inflammatory milieu that in turn favors NET formation. However, the direct and critical involvement of NETs was apparent from the tumor-protective and accelerated regenerative effect of DNase1 treatment during early post-wounding stages ( Figures 4C and 4E) .
NET formation has been documented in murine breast cancer tumors, and metastatic cancer cells can induce NETs, thereby promoting cancer dissemination . NET formation through neutrophil priming has also been shown to favor tumor growth (Demers et al., 2016) , together suggesting the importance of NET formation for cancer. Our study proves that the initial burst of NET formation caused by epithelial injury in the skin critically promotes tumor initiation and is mediated by epithelial-derived HMGB1 release.
Our observations in RDEB patients, in which we demonstrate the presence of NETs in lesional skin and SCCs ( Figure 6A ), indicate that these molecular events are relevant to human disease. We propose that anti-HMGB1, anti-TNF, or anti-NET therapies might be of particular interest in such patients, as well as in wound care of diabetic patients suffering from chronic ulcers, since these therapies could ameliorate wound healing responses, while limiting the risk of cutaneous tumorigenicity. Finally, this newly identified role of HMGB1 in mediating tumorigenicity of wounds through NET formation might well represent a signaling cascade that impacts on other barrier tissues where trauma is linked to tumor formation, such as in lung, liver, or the intestine, suggesting that HMGB1 targeting or prevention of NET formation might also be beneficial as a therapy in such disease conditions.
